Citurgia Biochem (506373)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• The stock has already fallen about 85% from its 52-week high of ₹212, removing much of the previous optimism.
• Reported trailing ROE of 9.06% suggests some positive equity return exists in earlier numbers, if the figure is reliable.
• The market cap of ₹418 Cr is small enough that a genuine operational restart could create meaningful per-share upside.

Concerns

• Latest quarter sales are ₹0 Cr and net profit is ₹-0 Cr, leaving no current earning power to value.
• ROCE of -2,150% signals severe operational value destruction on a tiny or eroded capital base.
• Piotroski F-Score of 2/9, profit growth of -190%, and no dividend indicate deep financial distress.
• Missing promoter holding, book value, and debt data create serious transparency and information risk.

AI Analysis

At ₹31.64, Citurgia Biochem looks less like a value bargain and more like a falling knife. The stock is 85% below its 52-week high of ₹212 and even trades below the stated 52-week low of ₹47.40. In Graham's world, price must be anchored to measurable value. Here, I have zero earnings visibility: latest quarter sales are ₹0 Cr and net profit is ₹-0 Cr. A P/E of 0.00 and no book value or P/B make a traditional margin-of-safety calculation impossible. The reported ROE of 9.06% is the only positive number, but with sales at zero and profit growth at -190%, I suspect that figure is backward-looking statistical noise. ROCE of -2,150% is catastrophic; it tells me management is destroying capital, not compounding it. The Piotroski F-Score of 2/9 reinforces the picture of a company in financial distress. This is a commodity chemical producer, so there is no pricing power or moat by definition. Without promoter holding data, dividends, or audited book value, I cannot separate a real hidden asset from a value trap. Buffett says it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. Here I don't even know if the company is fair. The market cap of ₹418 Cr may look small, but small is not cheap. I will not speculate on a possible turnaround without evidence of sales restoration, a healthier balance sheet, and positive returns on capital. A permanent loss of capital is my biggest fear. This is a pass for me until the numbers show a business again.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer